These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 33098043)

  • 1. In Vitro Evaluation and Biodistribution Studies of HPMA Copolymers Targeting the Gastrin Releasing Peptide Receptor in Prostate Cancer.
    Alshehri S; Fan W; Zhang W; Garrison JC
    Pharm Res; 2020 Oct; 37(11):229. PubMed ID: 33098043
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 18F-labeled bombesin analogs for targeting GRP receptor-expressing prostate cancer.
    Zhang X; Cai W; Cao F; Schreibmann E; Wu Y; Wu JC; Xing L; Chen X
    J Nucl Med; 2006 Mar; 47(3):492-501. PubMed ID: 16513619
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Theranostic Perspectives in Prostate Cancer with the Gastrin-Releasing Peptide Receptor Antagonist NeoBOMB1: Preclinical and First Clinical Results.
    Nock BA; Kaloudi A; Lymperis E; Giarika A; Kulkarni HR; Klette I; Singh A; Krenning EP; de Jong M; Maina T; Baum RP
    J Nucl Med; 2017 Jan; 58(1):75-80. PubMed ID: 27493272
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A new (68)Ga-labeled BBN peptide with a hydrophilic linker for GRPR-targeted tumor imaging.
    Pan D; Xu YP; Yang RH; Wang L; Chen F; Luo S; Yang M; Yan Y
    Amino Acids; 2014 Jun; 46(6):1481-9. PubMed ID: 24633452
    [TBL] [Abstract][Full Text] [Related]  

  • 5. microPET and autoradiographic imaging of GRP receptor expression with 64Cu-DOTA-[Lys3]bombesin in human prostate adenocarcinoma xenografts.
    Chen X; Park R; Hou Y; Tohme M; Shahinian AH; Bading JR; Conti PS
    J Nucl Med; 2004 Aug; 45(8):1390-7. PubMed ID: 15299066
    [TBL] [Abstract][Full Text] [Related]  

  • 6. GRPR-selective PET imaging of prostate cancer using [(18)F]-lanthionine-bombesin analogs.
    Carlucci G; Kuipers A; Ananias HJ; de Paula Faria D; Dierckx RA; Helfrich W; Rink R; Moll GN; de Jong IJ; Elsinga PH
    Peptides; 2015 May; 67():45-54. PubMed ID: 25797109
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Radiochemical investigations of 177Lu-DOTA-8-Aoc-BBN[7-14]NH2: an in vitro/in vivo assessment of the targeting ability of this new radiopharmaceutical for PC-3 human prostate cancer cells.
    Smith CJ; Gali H; Sieckman GL; Hayes DL; Owen NK; Mazuru DG; Volkert WA; Hoffman TJ
    Nucl Med Biol; 2003 Feb; 30(2):101-9. PubMed ID: 12623108
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [64Cu-NOTA-8-Aoc-BBN(7-14)NH2] targeting vector for positron-emission tomography imaging of gastrin-releasing peptide receptor-expressing tissues.
    Prasanphanich AF; Nanda PK; Rold TL; Ma L; Lewis MR; Garrison JC; Hoffman TJ; Sieckman GL; Figueroa SD; Smith CJ
    Proc Natl Acad Sci U S A; 2007 Jul; 104(30):12462-7. PubMed ID: 17626788
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Investigation of bombesin peptide as a targeting ligand for the gastrin releasing peptide (GRP) receptor.
    Begum AA; Moyle PM; Toth I
    Bioorg Med Chem; 2016 Nov; 24(22):5834-5841. PubMed ID: 27670095
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Optimization, biological evaluation and microPET imaging of copper-64-labeled bombesin agonists, [64Cu-NO2A-(X)-BBN(7-14)NH2], in a prostate tumor xenografted mouse model.
    Lane SR; Nanda P; Rold TL; Sieckman GL; Figueroa SD; Hoffman TJ; Jurisson SS; Smith CJ
    Nucl Med Biol; 2010 Oct; 37(7):751-61. PubMed ID: 20870150
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel Gastrin-Releasing Peptide Receptor Targeted Near-Infrared Fluorescence Dye for Image-Guided Surgery of Prostate Cancer.
    Pagoto A; Garello F; Marini GM; Tripepi M; Arena F; Bardini P; Stefania R; Lanzardo S; Valbusa G; Porpiglia F; Manfredi M; Aime S; Terreno E
    Mol Imaging Biol; 2020 Feb; 22(1):85-93. PubMed ID: 31025163
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting tumor angiogenesis: comparison of peptide and polymer-peptide conjugates.
    Line BR; Mitra A; Nan A; Ghandehari H
    J Nucl Med; 2005 Sep; 46(9):1552-60. PubMed ID: 16157540
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Organometallic 99mTc(III) '4 + 1' bombesin(7-14) conjugates: synthesis, radiolabeling, and in vitro/in vivo studies.
    Kunstler JU; Veerendra B; Figueroa SD; Sieckman GL; Rold TL; Hoffman TJ; Smith CJ; Pietzsch HJ
    Bioconjug Chem; 2007; 18(5):1651-61. PubMed ID: 17663527
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative in vitro and in vivo evaluation of two 64Cu-labeled bombesin analogs in a mouse model of human prostate adenocarcinoma.
    Yang YS; Zhang X; Xiong Z; Chen X
    Nucl Med Biol; 2006 Apr; 33(3):371-80. PubMed ID: 16631086
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effects of linking substituents on the in vivo behavior of site-directed, peptide-based, diagnostic radiopharmaceuticals.
    Prasanphanich AF; Lane SR; Figueroa SD; Ma L; Rold TL; Sieckman GL; Hoffman TJ; McCrate JM; Smith CJ
    In Vivo; 2007; 21(1):1-16. PubMed ID: 17354608
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gastrin-releasing peptide receptor (GRPr) promotes EMT, growth, and invasion in canine prostate cancer.
    Elshafae SM; Hassan BB; Supsavhad W; Dirksen WP; Camiener RY; Ding H; Tweedle MF; Rosol TJ
    Prostate; 2016 Jun; 76(9):796-809. PubMed ID: 26939805
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bombesin analogues for gastrin-releasing peptide receptor imaging.
    Nanda PK; Pandey U; Bottenus BN; Rold TL; Sieckman GL; Szczodroski AF; Hoffman TJ; Smith CJ
    Nucl Med Biol; 2012 May; 39(4):461-71. PubMed ID: 22261143
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Selection of optimal chelator improves the contrast of GRPR imaging using bombesin analogue RM26.
    Mitran B; Varasteh Z; Selvaraju RK; Lindeberg G; Sörensen J; Larhed M; Tolmachev V; Rosenström U; Orlova A
    Int J Oncol; 2016 May; 48(5):2124-34. PubMed ID: 26983776
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effect of macrocyclic chelators on the targeting properties of the 68Ga-labeled gastrin releasing peptide receptor antagonist PEG2-RM26.
    Varasteh Z; Mitran B; Rosenström U; Velikyan I; Rosestedt M; Lindeberg G; Sörensen J; Larhed M; Tolmachev V; Orlova A
    Nucl Med Biol; 2015 May; 42(5):446-454. PubMed ID: 25684649
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preclinical and first clinical experience with the gastrin-releasing peptide receptor-antagonist [⁶⁸Ga]SB3 and PET/CT.
    Maina T; Bergsma H; Kulkarni HR; Mueller D; Charalambidis D; Krenning EP; Nock BA; de Jong M; Baum RP
    Eur J Nucl Med Mol Imaging; 2016 May; 43(5):964-973. PubMed ID: 26631238
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.